• Consider starting HU in proliferative AML which helps to delay induction if necessary • Eligible patients: 3 + 7 regimen • Non-eligible patients: hypomethylating agents (±Venetoclax) • Targeted therapy for FLT3 or IDH 1/2 mutations should be given • Mylotarg (Anti CD33) for CBF AML patients • G-CSF to shorten neutropenia • Lowering transfusion episodes, by lowering thresholds for Hb (<7 g/dl) and platelets (<10 × 109/L). Here, FLT3 is linked to Decreased total neutrophil count.